Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dystrophinopathies

B Reitter1, H H Goebel

  • 1Department of Pediatrics, Mainz University Medical Center, Germany.

Seminars in Pediatric Neurology
|June 1, 1996
PubMed
Summary
This summary is machine-generated.

The discovery of dystrophin protein has redefined dystrophinopathies, improving diagnosis for Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) carriers. Current therapies, including myoblast transplantation, have not shown clinical improvement.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neuronal ceroid lipofuscinosis (NCL) is caused by the entire deletion of CLN8 in the Alpenländische Dachsbracke dog.

Molecular genetics and metabolism·2016
Same author

Protein aggregation in inclusion body myositis, a sporadic form among protein aggregate myopathies, and in myofibrillar myopathies--a comparative study.

Romanian journal of internal medicine = Revue roumaine de medecine interne·2011
Same author

Familial reducing body myopathy with cytoplasmic bodies and rigid spine revisited: identification of a second LIM domain mutation in FHL1.

Neuropediatrics·2010
Same author

CLN5 mutations are frequent in juvenile and late-onset non-Finnish patients with NCL.

Neurology·2010
Same author

Macrophagic myofasciitis plus (distinct types of muscular dystrophy).

Neuropediatrics·2010
Same author

Consequences of mutations within the C terminus of the FHL1 gene.

Neurology·2009
Same journal

Concussion in contact sport: risks, detection, & prevention.

Seminars in pediatric neurology·2026
Same journal

A multidisciplinary, symptom-targeted approach to rehabilitation in pediatric concussion.

Seminars in pediatric neurology·2026
Same journal

Pediatric concussion beyond sports: Falls, play, and everyday activities.

Seminars in pediatric neurology·2026
Same journal

Return-to-school protocols in pediatric concussion care.

Seminars in pediatric neurology·2026
Same journal

Improving concussion recognition in youth sports: the role of parents, coaches, and community education.

Seminars in pediatric neurology·2026
Same journal

Concussion management, rehabilitation, and societal impact.

Seminars in pediatric neurology·2026
See all related articles

Area of Science:

  • Neurology
  • Genetics
  • Biochemistry

Background:

  • Dystrophinopathies encompass Duchenne (DMD) and Becker (BMD) muscular dystrophies.
  • The protein dystrophin is crucial for muscle fiber integrity.
  • Understanding dystrophin has advanced the classification of these neuromuscular disorders.

Purpose of the Study:

  • To review the impact of dystrophin discovery on dystrophinopathy classification and diagnosis.
  • To highlight advancements in carrier detection and prenatal diagnosis.
  • To assess the current status of therapeutic interventions for dystrophinopathies.

Main Methods:

  • Immunohistochemical analysis of dystrophin.
  • Western blot analysis for dystrophin.
  • Review of molecular genetics and therapeutic trial outcomes.

Related Experiment Videos

Main Results:

  • Dystrophin analysis expanded the clinical spectrum of dystrophinopathies.
  • Carrier detection for DMD is more reliable, especially in manifesting carriers.
  • Prenatal diagnosis can identify affected male fetuses.
  • Molecular genetics provided detailed insights into dystrophinopathies.
  • Therapeutic approaches, including myoblast transplantation, have not yielded clinical improvement.

Conclusions:

  • Dystrophin discovery has refined the nosology of DMD and BMD into dystrophinopathies.
  • Diagnostic capabilities for dystrophinopathies have significantly improved.
  • Effective therapies for dystrophinopathies remain a critical unmet need.